CalciMedica (NASDAQ:CALC) Announces Quarterly Earnings Results, Beats Expectations By $0.06 EPS

CalciMedica (NASDAQ:CALC) announced its quarterly earnings data on Tuesday. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.06, Zacks reports.

CalciMedica Stock Up 1.7%

Shares of NASDAQ:CALC traded up $0.01 during trading on Tuesday, hitting $0.60. 42,381 shares of the company traded hands, compared to its average volume of 902,643. The stock has a market capitalization of $9.46 million, a price-to-earnings ratio of -0.31 and a beta of 0.85. The business’s fifty day moving average is $0.63 and its 200-day moving average is $2.57. CalciMedica has a one year low of $0.46 and a one year high of $7.20.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on CALC. HC Wainwright reissued a “neutral” rating on shares of CalciMedica in a report on Thursday, January 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of CalciMedica in a report on Wednesday, January 21st. Oppenheimer lowered their price objective on CalciMedica from $20.00 to $10.00 and set an “outperform” rating for the company in a report on Thursday, March 5th. Finally, Wall Street Zen raised CalciMedica to a “sell” rating in a report on Saturday, January 17th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $13.00.

Hedge Funds Weigh In On CalciMedica

Institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC bought a new position in shares of CalciMedica during the fourth quarter valued at approximately $127,000. Cetera Investment Advisers grew its holdings in shares of CalciMedica by 33.1% during the second quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after purchasing an additional 9,045 shares during the last quarter. Boothbay Fund Management LLC bought a new position in shares of CalciMedica during the fourth quarter valued at approximately $506,000. Renaissance Technologies LLC grew its holdings in shares of CalciMedica by 26.1% during the fourth quarter. Renaissance Technologies LLC now owns 88,300 shares of the company’s stock valued at $582,000 after purchasing an additional 18,300 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its holdings in shares of CalciMedica by 58.2% during the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after purchasing an additional 34,386 shares during the last quarter.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.